A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. / Gjorup, I.; Roikjaer, O.; Andersen, B.; Burcharth, F.; Hovendal, C.; Pedersen, S. A.; Christiansen, P.; Wara, P.; Andersen, J. C.; Balslev, I.; Jepsen, J.; Rokkjaer, M.
I: Surgery Gynecology and Obstetrics, Bind 175, Nr. 5, 01.01.1992, s. 397-400.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis
AU - Gjorup, I.
AU - Roikjaer, O.
AU - Andersen, B.
AU - Burcharth, F.
AU - Hovendal, C.
AU - Pedersen, S. A.
AU - Christiansen, P.
AU - Wara, P.
AU - Andersen, J. C.
AU - Balslev, I.
AU - Jepsen, J.
AU - Rokkjaer, M.
PY - 1992/1/1
Y1 - 1992/1/1
N2 - To evaluate the effect of somatostatin in the treatment of acute pancreatitis, 63 patients were randomly allocated to continuous intravenous infusion for three days of 250 micrograms of somatostatin (Dura Scan, Odense, Denmark) per hour (n=33), or placebo (n=30). Patients with a first attack of pancreatitis, serum amylase level of more than 450 units per liter and symptoms for less than 24 hours were eligible for participation in the study. Apart from a slightly significant faster decrease in serum amylase concentrations, we were unable to demonstrate any significant benefit from somatostatin with regard to paraclinical values and clinical course.
AB - To evaluate the effect of somatostatin in the treatment of acute pancreatitis, 63 patients were randomly allocated to continuous intravenous infusion for three days of 250 micrograms of somatostatin (Dura Scan, Odense, Denmark) per hour (n=33), or placebo (n=30). Patients with a first attack of pancreatitis, serum amylase level of more than 450 units per liter and symptoms for less than 24 hours were eligible for participation in the study. Apart from a slightly significant faster decrease in serum amylase concentrations, we were unable to demonstrate any significant benefit from somatostatin with regard to paraclinical values and clinical course.
UR - http://www.scopus.com/inward/record.url?scp=0026498680&partnerID=8YFLogxK
M3 - Journal article
C2 - 1279821
AN - SCOPUS:0026498680
VL - 175
SP - 397
EP - 400
JO - SURGERY GYNECOLOGY & OBSTETRICS
JF - SURGERY GYNECOLOGY & OBSTETRICS
SN - 0039-6087
IS - 5
ER -
ID: 203892951